



# REGIONAL ADULT PARENTERAL DRUG MONOGRAPH

GENERIC NAME  
**inFLIXimab**

**Effective Date:** May 2013

CLASSIFICATION  
**Immunomodulator**

OTHER NAMES  
**Remicade**

PAGE  
1 of 2

**Revised Date:** Nov 2024

**ADMINISTRATION POLICY:**

- IV Intermittent: - May be administered by a nurse
- IV bolus: - *Not recommended*
- IM/Subcut: - *Not recommended*

**RECONSTITUTION/DILUTION/ADMINISTRATION:**

**Available as:** 100 mg vial REFRIGERATE

**Reconstitution:** Add 10 mL sterile water for injection down the wall of the vial. Gently rotate the vial to dissolve and let stand for 5 minutes. **DO NOT SHAKE.** Discard vial after use.  
Final concentration: 10 mg/mL      Final Volume: 10 mL

**IV Intermittent:** Administer with inline 0.2 to 1.2 micron filter.

Dose	Dose Preferred Diluent Volumes Bag size NaCl 0.9%
660 mg or less	250 mL
661 to 116 0mg	250 mL (remove 50 mL's prior to addition of medication)
1161 mg or greater	500 mL (remove volume equivalent of dose volume prior to addition of medication)

Standard Infusion Protocol (for infliximab naïve patient): Administer over at least 2 hours.  
Rate: 30 mL/hour for 15 minutes then 60 mL/hour for 30 minutes then 125 mL/hour to complete infusion

Shortened Infusion Protocol (for patients who have tolerated previous doses):  
Administer over at least 1 hour.  
Rate: 40 mL/hour for 15 minutes then 250-300 mL/hour to complete infusion

**DOSAGE:**

- Rheumatoid arthritis:** 3 mg/kg. Repeat dose at 2 and 6 week intervals after first infusion, then every 8 weeks thereafter.
- Crohn's disease (fistulizing)** Induction: 5 mg/kg/dose x 1. Repeat dose at 2 & 6 after the first infusion
- Maximum rate:** **IV infusion:** 125 mL/hour (over at least 2 hours)  
Shortened-Infusion Protocol: over at least 1 hour
- Maximum concentration:** 4 mg/mL (i.e. maximum 10 vials (1000 mg) per 250 mL normal saline; 20 vials in 500 mL; 4 vials in 100 mL; 2 vials in 50 mL, etc.)
- Maximum single dose:** 10 mg/kg

**STABILITY/COMPATIBILITY:**

- Stability of reconstituted mixture:** 24 hours at room temperature
- Stability of Final Admixture:** 24 hours at room temperature

**Compatibility:** Compatible with normal saline. *Do NOT mix with other drugs.*



# REGIONAL ADULT PARENTERAL DRUG MONOGRAPH

	GENERIC NAME <b>inFLIXimab</b>		
<b>Effective Date:</b> May 2013  <b>Revised Date:</b> Nov 2024	CLASSIFICATION <b>Immunomodulator</b>	OTHER NAMES <b>Remicade</b>	PAGE 2 of 2
<b>PRECAUTIONS, POTENTIAL ADVERSE REACTIONS:</b> <b>Acute</b> <u><b>Mild:</b></u> Flushing, dizziness, headache, diaphoresis, nausea, palpitations <u><b>Moderate:</b></u> Chest discomfort, shortness of breath, hypo/hypertension (>20 points SBP), increased temperature, palpitations, urticaria <u><b>Severe:</b></u> Hypo/hypertension (>40 points SBP), increased temperature with rigors, chest discomfort, shortness of breath with wheezing, stridor, flushing  <b>Delayed</b> Rash/urticaria, myalgias, flu-like symptoms, joint stiffness and pain, headache			
<b>ADDITIONAL NOTES AND NURSING CONSIDERATIONS:</b> <ul style="list-style-type: none"> <li>• Do not use the solution if discolored or opaque particles present. The solution should be colorless to pale yellow and may develop a few translucent particles since the drug is a protein. Foaming of the solution is not unusual – avoid agitation to reduce foaming in the admixture bag and IV line.</li> <li>• Monitor blood pressure, pulse and temperature prior to infusion, every 30 minutes during infusion and every 30 minutes for 1 hour after the infusion.</li> <li>• For patients receiving the shortened infusion protocol monitor blood pressure, pulse and temperature prior to infusion, with the rate change to 250-300 mL/hour and when the infusion is complete prior to discharge.</li> <li>• Shortened Infusion Protocol: For patients NOT previously treated with this drug, infliximab should be administered over a minimum of 2 hours. At the discretion of the prescribing physician, patients who have tolerated three initial 2 hour infusions of infliximab without adverse effects may be considered for receiving subsequent infusions at the same dose over a period of at least one hour.</li> <li>• InFLIXimab is stable for 6 months at room temperature if accidentally left out of the fridge.</li> <li>• inFLIXimab will be supplied/brought in by the patient</li> </ul>			